Table 1.

Clinical characteristics of the VEBIOS discovery study

89 Cases88 Controls
VariablesNFreq.NFreq.
Localization of the thrombosis     
 DVT, lower limbs 47 0.53   
  Proximal 36 0.77   
 PE 45 0.51   
Gender and biometry     
 Gender, women 35 0.39 35 0.39 
 Age, y (mean ± SD and range) 51.1 ± 10.8 (20-70) 51.6 ± 10.8 (21-70) 
 BMI, kg/m2 (mean ± SD and range) 26.7 ± 4.6 (17-46) 25.6 ± 4 (19-38) 
 Obese, BMI ≥ 30 kg/m2 20 0.22 16 0.19 
Cardiovascular risk factors     
 Hypertension* 19 0.21 10 0.11 
 Hyperlipidemia* 0.06 0.06 
 Diabetes mellitus* 0.02 0.06 
 Current smoking 15 0.17 0.08 
Family history     
 VTE, first-degree relative <60 y old 15 0.17 0.01 
Provoked risk factors 39 0.44 17 0.19 
 Trauma 22 0.22 0.08 
 Cast, orthosis, etc 15 0.17 0.01 
 Surgery 16 0.18 0.02 
 Pregnancy, postpartum 3 mo 
 Contraceptives§ 11 0.31 0.26 
 Menopausal replacement therapy# 0.14 0.03 
89 Cases88 Controls
VariablesNFreq.NFreq.
Localization of the thrombosis     
 DVT, lower limbs 47 0.53   
  Proximal 36 0.77   
 PE 45 0.51   
Gender and biometry     
 Gender, women 35 0.39 35 0.39 
 Age, y (mean ± SD and range) 51.1 ± 10.8 (20-70) 51.6 ± 10.8 (21-70) 
 BMI, kg/m2 (mean ± SD and range) 26.7 ± 4.6 (17-46) 25.6 ± 4 (19-38) 
 Obese, BMI ≥ 30 kg/m2 20 0.22 16 0.19 
Cardiovascular risk factors     
 Hypertension* 19 0.21 10 0.11 
 Hyperlipidemia* 0.06 0.06 
 Diabetes mellitus* 0.02 0.06 
 Current smoking 15 0.17 0.08 
Family history     
 VTE, first-degree relative <60 y old 15 0.17 0.01 
Provoked risk factors 39 0.44 17 0.19 
 Trauma 22 0.22 0.08 
 Cast, orthosis, etc 15 0.17 0.01 
 Surgery 16 0.18 0.02 
 Pregnancy, postpartum 3 mo 
 Contraceptives§ 11 0.31 0.26 
 Menopausal replacement therapy# 0.14 0.03 

freq., frequency; N, numbers; SD, standard deviation.

*

Medical treatment.

Daily within the last year.

Within 3 mo from diagnose or index date.

§

Estrogen containing (oral, patch, vaginal devices).

#

Estrogen containing (oral only).

Close Modal

or Create an Account

Close Modal
Close Modal